60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) is one of the best up and coming penny stocks to buy. On February 2, 60 Degrees Pharmaceuticals announced a partnership with GoodRx to enhance the affordability and accessibility of ARAKODA (tafenoquine), the only FDA-approved, once-weekly prescription medication for malaria prevention in the US. The collaboration allows eligible patients to save up to 30% on the treatment at over 70,000 pharmacies nationwide. This initiative is a key part of the company’s st ...

Core Insights - 60 Degrees Pharmaceuticals, Inc. has announced a partnership with GoodRx to provide savings of up to 30% on ARAKODA (tafenoquine) for eligible consumers [1][10] - ARAKODA is the only FDA-approved, once-weekly malaria prevention medication available in the U.S. market, making it a preferred choice for travelers to malaria-endemic regions [2][6] Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing new medicines for vector-borne diseases and received FDA approval for ARAKODA in 2018 [19] - The company is headquartered in Washington, D.C., and has a subsidiary in Australia, with ARAKODA commercially available in both countries [19] Product Information - ARAKODA (tafenoquine) is indicated for malaria prophylaxis in patients aged 18 and older and has a long terminal half-life of approximately 16 days, allowing for less frequent dosing [7][8] - The medication was discovered by the Walter Reed Army Institute of Research and has undergone extensive safety assessments in clinical trials [5][6] Partnership Details - The collaboration with GoodRx aims to lower out-of-pocket costs for patients and expand the marketing reach of ARAKODA, making it accessible at over 70,000 pharmacies nationwide [10][4] - Eligible patients can access a low self-pay price for ARAKODA through GoodRx starting February 2, 2026 [4][10]

U.S. Stock Market - U.S. stocks traded higher, with the Dow Jones index gaining more than 100 points, up 0.33% to 49,259.65 [1] - The NASDAQ increased by 0.09% to 23,521.63, and the S&P 500 rose 0.26% to 6,933.84 [1] - Materials shares gained 0.8%, while health care stocks dipped by 0.2% [1] Company Earnings - Steel Dynamics Inc reported fourth-quarter earnings of $1.82 per share, missing the analyst consensus estimate of $1.95 per share [2] - The company also reported quarterly sales of $4.414 billion, which fell short of the analyst consensus estimate of $4.575 billion [2] Commodity Market - Oil prices decreased by 0.6% to $60.72, while gold prices increased by 1.8% to $5,068.50 [4] - Silver rose by 8.1% to $109.565, and copper increased by 0.5% to $5.9770 [4] Asian Markets - Asian markets closed mixed, with Japan's Nikkei falling 1.79%, Hong Kong's Hang Seng Index gaining 0.06%, and China's Shanghai Composite declining 0.09% [6] Stock Movements - Battalion Oil Corp shares surged 379% to $6.13 after switching gas processing partners and boosting production [8] - Brand Engagement Network Inc shares increased by 196% to $48.79 following a strategic partnership announcement [8] - Gaxos.ai Inc shares rose 76% to $1.97, while Mingteng International Corp shares dropped 36% to $2.16 [8] - CN ENERGY GROUP Inc shares fell 35% to $0.52 due to a Nasdaq delisting determination [8] - 60 Degrees Pharmaceuticals Inc shares decreased by 23% to $3.52 after a 10% drop on Friday [8] Economic Indicators - U.S. durable-goods orders rose 5.3% month-over-month in November, surpassing market estimates of a 3.7% increase [9]

Company Performance - Spring Valley Acquisition Corp. III Warrants (NASDAQ:SVACW) experienced a significant price increase of 294.23%, reaching $2.05, potentially driven by speculative trading or news related to their energy and decarbonization operations [1][6] - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) saw its stock price rise by 144.5% to $4.89, likely benefiting from positive clinical trial developments or regulatory approvals, despite a 1-4 reverse stock split leading to a 2.4% decline ahead of the event [2] - IO Biotech, Inc. (NASDAQ:IOBT) had a stock price increase of 102.12%, reaching $0.41, with investor optimism possibly fueled by its focus on immune-modulating cancer therapies and exploration of strategic alternatives [3][6] - Namib Minerals Warrants (NASDAQ:NAMMW) recorded an 88.68% increase to $0.34, influenced by its involvement in gold and critical green metals production and exploration, while Namib Minerals Ordinary Shares (NASDAQ:NAMM) rose by 77.47% to $4.01, possibly due to favorable mining outcomes or strategic acquisitions [4] Market Dynamics - The recent stock price movements highlight the dynamic nature of the market, where company developments, industry trends, and investor sentiment play crucial roles in influencing stock prices [5]

Company Performance - Abbott Laboratories (NYSE:ABT) stock fell over 7% after reporting fourth-quarter 2025 sales of $11.46 billion, slightly missing the consensus estimate of $11.80 billion, with a sales increase of 4.4% on a reported basis and 3% on an organic basis [2][3] - The company reported adjusted earnings of $1.50, which was in line with Wall Street estimates [3] Market Movements - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares surged 158% to $5.15 following a partnership announcement with Runway Health [9] - Eagle Bancorp, Inc. (NASDAQ:EGBN) shares increased by 18% to $28.25 after reporting better-than-expected fourth-quarter financial results [9] - Creative Media & Community Trust Corporation (NASDAQ:CMCT) shares rose 52% to $4.4494 after closing the sale of its lending division [9] - C3is Inc. (NASDAQ:CISS) shares dropped 37% to $0.088 after announcing a 1-for-20 reverse stock split [9] - Mingteng International Corporation Inc. (NASDAQ:MTEN) shares fell 34% to $0.020 following a 1-for-200 reverse stock split [9] - POET Technologies Inc. (NASDAQ:POET) shares decreased by 12% to $7.35 after announcing a $150 million offering of 20.690 million shares [9]

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 200 points on Thursday [1] - The Dow rose by 0.78% to 49,462.35, the NASDAQ gained 0.94% to 23,443.19, and the S&P 500 increased by 0.63% to 6,918.78 [1] Company Performance - Abbott Laboratories (NYSE:ABT) saw its stock decline by over 7% after reporting fourth-quarter 2025 sales of $11.46 billion, which fell short of the consensus estimate of $11.80 billion [2] - The sales represented a 4.4% increase on a reported basis and a 3% increase on an organic basis, or 3.8% when excluding COVID-19 testing-related sales [2] - Abbott's adjusted earnings were reported at $1.50, aligning with Wall Street estimates [3] Sector Performance - Communication services shares increased by 1.3% on Thursday [1] - Utilities stocks experienced a decline of 0.5% in trading on Wednesday [1] Commodity Market - Oil prices decreased by 2.1% to $59.37, while gold prices increased by 0.6% to $4,864.60 [6] - Silver prices rose by 2.7% to $95.135, whereas copper prices fell by 0.4% to $5.7435 [6] Global Market Trends - European shares showed positive movement, with the eurozone's STOXX 600 gaining 1.09% and Spain's IBEX 35 Index rising by 1.01% [7] - Asian markets also closed higher, with Japan's Nikkei gaining 1.73% and India's BSE Sensex rising by 0.49% [8] Notable Stock Movements - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares surged by 158% to $5.15 following a partnership announcement [9] - Eagle Bancorp, Inc. (NASDAQ:EGBN) shares increased by 18% to $28.25 after reporting better-than-expected fourth-quarter financial results [9] - Creative Media & Community Trust Corporation (NASDAQ:CMCT) shares rose by 52% to $4.4494 after closing the sale of its lending division [9] - C3is Inc. (NASDAQ:CISS) shares dropped by 37% to $0.088 due to a 1-for-20 reverse stock split announcement [9] - Mingteng International Corporation Inc. (NASDAQ:MTEN) shares fell by 34% to $0.020 after announcing a 1-for-200 reverse stock split [9] - POET Technologies Inc. (NASDAQ:POET) shares decreased by 12% to $7.35 following a $150 million offering of 20.690 million shares [9]

Market Overview - U.S. stocks traded higher, with the Dow Jones index gaining approximately 300 points, up 0.63% to 49,387.01, NASDAQ up 0.77% to 23,402.89, and S&P 500 up 0.51% to 6,910.38 [1] Sector Performance - Communication services shares increased by 1.7% on Thursday, while energy stocks dipped by 0.4% on Wednesday [2] Company News - Procter & Gamble Company (NYSE:PG) stock rose around 2% after reporting second-quarter adjusted earnings per share of $1.88, exceeding the analyst consensus estimate of $1.86, although quarterly sales of $22.208 billion fell short of the expected $22.282 billion [3] Commodity Market - Oil prices decreased by 1.9% to $59.47, while gold prices increased by 0.2% to $4,845.00. Silver rose by 1.7% to $94.215, and copper fell by 0.4% to $5.7450 [5] European Market - European shares were higher, with the eurozone's STOXX 600 gaining 1.4%, Spain's IBEX 35 Index up 1.5%, London's FTSE 100 up 0.7%, Germany's DAX up 1.5%, and France's CAC 40 up 1.5% [6] Asian Market - Asian markets closed higher, with Japan's Nikkei gaining 1.73%, Hong Kong's Hang Seng Index up 0.17%, China's Shanghai Composite up 0.14%, and India's BSE Sensex rising 0.49% [7] Notable Stock Movements - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares surged 297% to $7.94 following a partnership announcement. iOThree Limited (NASDAQ:IOTR) shares increased by 80% to $5.28, and Creative Media & Community Trust Corporation (NASDAQ:CMCT) shares rose 63% to $4.7750 after closing the sale of its lending division. Conversely, C3is Inc. (NASDAQ:CISS) shares dropped 37% to $0.0888 due to a reverse stock split announcement [9] Economic Indicators - U.S. initial jobless claims rose by 1,000 to 200,000 for the week ending Jan. 17. The U.S. economy grew at an annualized rate of 4.4% in the third quarter, surpassing the preliminary estimate of 4.3% and marking the strongest growth since the third quarter of 2023 [10]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - iOThree Limited (IOTR) has increased by 177% to $8.12 - 60 Degrees Pharmaceuticals, Inc. (SXTP) has risen by 90% to $3.81 - Greenwich LifeSciences, Inc. (GLSI) is up 52% at $33.98 - Erayak Power Solution Group Inc. (RAYA) has gained 30% to $3.12 - High Roller Technologies, Inc. (ROLR) is up 24% at $9.87 - Cabaletta Bio, Inc. (CABA) has increased by 12% to $2.63 - Nvni Group Limited (NVNI) is up 10% at $3.23 - Karman Holdings Inc. (KRMN) has risen by 9% to $114.79 - Venture Global, Inc. (VG) is up 9% at $9.87 - Oportun Financial Corporation (OPRT) has increased by 9% to $5.32 [3] Premarket Losers - Yunhong Green CTI Ltd. (YHGJ) has decreased by 11% to $4.20 - GlucoTrack, Inc. (GCTK) is down 11% at $3.45 - Black Titan Corporation (BTTC) has fallen by 11% to $2.08 - Lee Enterprises, Incorporated (LEE) is down 10% at $5.02 - Namib Minerals (NAMM) has decreased by 10% to $2.02 - Top Wealth Group Holding Limited (TWG) is down 7% at $4.10 - Axogen, Inc. (AXGN) has fallen by 6% to $30.86 - iPower Inc. (IPW) is down 6% at $4.60 - Masonglory Limited (MSGY) has decreased by 5% to $5.11 - Bonk, Inc. (BNKK) is down 5% at $4.56 [4]

Core Viewpoint - 60 Degrees Pharmaceuticals, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, showcasing its focus on developing new medicines for vector-borne diseases [1][2]. Company Overview - 60 Degrees Pharmaceuticals, Inc. specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne diseases, with its lead product ARAKODA® (tafenoquine) approved by the U.S. FDA for malaria prevention in 2018 [3]. - ARAKODA is commercially available in the U.S. and Australia, and the company collaborates with prominent research and academic organizations in both countries [3]. Conference Participation - Dr. Geoff Dow, CEO of 60 Degrees Pharmaceuticals, will present live on September 10 at 2:30 ET, and the company management will conduct one-on-one meetings during the conference [2]. - Attendees can request meetings with management through the conference portal or directly with the company [2]. Webcast Information - A live webcast of the presentation will be available, with a replay accessible for approximately 90 days on the company's investor page [3].

Core Insights - 60 Degrees Pharmaceuticals, Inc. has revealed that the actual burden of babesiosis in the U.S. may be significantly higher than CDC statistics indicate, with nearly 3 million Americans potentially diagnosed with the disease [1][2][9] - The survey conducted by the company suggests that babesiosis is underdiagnosed or underreported, indicating a greater demand for effective treatment than current CDC statistics suggest [2][5] - The company is developing treatment candidates for babesiosis and aims to define the commercial market size for these treatments [5][12] Survey Findings - The survey included 6,000 participants and found that 1.26% of respondents reported a diagnosis of babesiosis, equating to approximately 3 million Americans [6][9] - About 17% of those diagnosed with babesiosis reported experiencing illness for six months or more, suggesting at least 570,000 adults may have chronic disease [6][9] - Approximately 3.7% of respondents reported experiencing chronic fatigue lasting longer than six months, which may be related to babesiosis [7][9] Medical Implications - Babesiosis is a serious tick-borne disease that can co-occur with Lyme disease and may be life-threatening for immunocompromised and elderly individuals [3][10] - There is a hypothesis that persistent Babesia infection may contribute to chronic fatigue, potentially affecting millions of Americans who are undiagnosed [4][8] - The company is conducting clinical trials to test the efficacy of ARAKODA (tafenoquine) in treating babesiosis, although it is currently only approved for malaria prophylaxis [12][13] Company Background - 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and specializes in developing new medicines for infectious diseases [14] - The company achieved FDA approval for its lead product, ARAKODA, in 2018 for malaria prevention and collaborates with research organizations in multiple countries [14]